Next Generation
in Protein

RedShiftBio provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality.

Biosimilar App note

Biosimilar Structural Comparison of Commercially Sourced Reference Standards by MMS Rapidly Detects Subtle but Critical Differences to Correctly Predict Activity for Use in an ELISA Product

  • This study confidently detected <2% structural difference between samples to correctly predict activity amongst the commercially sourced materials.
  • MMS successfully identifies the 5 of 13 BSA biosimilar samples that retained acceptable activity upon inclusion in the ELISA product through structural comparison to a reference of known activity.

The Next Generation in Protein Characterization

The AQS3pro brings protein secondary structure measurement into every stage of the biopharmaceutical pipeline. The AQS3pro generates repeatable, automated measurements with high sensitivity in complex formulation conditions that are not possible with traditional analytical methods.


Investigate change and download our latest literature